Health
Medeze Group Awarded Frost & Sullivan's 2024 Southeast Asia Company of the Year for Delivering Highly Innovative Stem Cell and Longevity Solutions
Medeze Group (Medeze) specializes in cutting-edge stem cell banking services, leveraging advanced cryopreservation techniques and pioneering therapies to enhance longevity and health outcomes. SAN ANTONIO, Oct. 18, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the stem cell banking a...
2024-10-18 15:00
1373
Getinge Interim Report July-September 2024: Strong order intake but temporary delivery disruptions had a negative impact on earnings
GOTHENBURG, Sweden, Oct. 18, 2024 /PRNewswire/ -- "The order intake increased by 10.0%, of which organic growth was 7.4%. All regions reported a positive performance," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased by 3.5%, of which the organic increase...
2024-10-18 14:42
1397
Ping An Health Upgrades Chronic Disease Management Services with Significant Results in Digital Weight Management Program
HONG KONG and SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- The Weight Management and Public Health Action Conference, hosted by the National Center for Chronic and Noncommunicable Disease Control and Prevention ("NCNCD") and its affiliated institution, the Binhai Institute for Chronic Disease Control ...
2024-10-18 12:13
2902
Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country
* This approval for XPOVIO® for the treatment of patients with multiple myeloma (MM) marks the third approved indication of the drug inSouth Korea. * To date, XPOVIO® has already been included in national health insurance or reimbursement schemes inSouth Korea, the mainland of China, Australia...
2024-10-18 10:35
2136
Columbia Asia Harnesses Solar Energy for Sustainable Healthcare
Partnership with Solarvest Energy Sdn Bhd Significantly Reduces Carbon Dioxide Emissions Across Nine Hospitals in The Country KUALA LUMPUR, Malaysia, Oct. 18, 2024 /PRNewswire/ -- Columbia Asia, one of Malaysia's largest chain of private hospitals and part of Asia OneHealthcare (A1Health) has of...
2024-10-18 09:00
1845
OmniaBio Announces Opening of New Commercial Manufacturing Facility in Canada, Bringing Life-Saving Cell and Gene Therapies to Patients
The site will add state-of-the-art CGT capacity and employ artificial intelligence and automation to achieve critical product supply efficiencies for North American and global biotherapy clients HAMILTON, ON, Oct. 18, 2024 /PRNewswire/ -- Today OmniaBio Inc. will announce the opening of a new No...
2024-10-18 07:00
1472
Telix Files Form 20-F Registration Statement for Nasdaq ADS
MELBOURNE, Australia, Oct. 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has publicly filed a Form 20-F registration statement (Registration Statement) withthe United States (U.S.) Securities and Exchange Commission (SEC) relating to a pro...
2024-10-18 05:32
1782
Press Announcement: AIMed24 Announces Strategic Partnership with Frost & Sullivan
SAN ANTONIO, Oct. 17, 2024 /PRNewswire/ -- AIMed24, the premier event for artificial intelligence and healthcare innovation, is excited to announce its strategic partnership with Frost & Sullivan. This collaboration will further enhance AIMed24's mission to advance healthcare with cutting-edge AI...
2024-10-17 23:01
1367
Ublives Introduces SoleFlux Relax Compression Boots: The Perfect Gift for Parents to Relieve Leg Pain
NEW YORK, Oct. 17, 2024 /PRNewswire/ -- Ublives has officially launched its latest innovation: the SoleFlux Relax Compression Boots. These boots are designed to effectively relieve leg pain and discomfort. They are not only an ideal gift for parents but also a practical solution for anyone suffer...
2024-10-17 22:00
1170
Exclusive Interview with Lang Guojun, founder of Sanyou Bio: The Key to Breaking the Bottleneck of New Drug Innovation--The Past and Future of the Super-Trillion Molecule Library
SHANGHAI, Oct. 17, 2024 /PRNewswire/ -- In the ninth year since the establishment of Sanyou Bio, Lang Guojun believes that the time is perfect to unveil the world's largest super-trillion molecule library. During the interview with Tongxieyi, he frankly and confidently expressed, "Nine years of ...
2024-10-17 22:00
1157
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted
SHENZHEN, China, Oct. 17, 2024 /PRNewswire/ -- On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company's Investigational New Drug (IND) application for CS231295 tablets, a Class 1 innovative drug for the treatment of t...
2024-10-17 21:38
1616
Amplo Biotechnology Announces Three Presentations at the European Society of Gene and Cell Therapy 31st Annual Congress
SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- Amplo Biotechnology, a biotechnology company developing genetic medicines for the treatment of neuromuscular diseases, announced the presentation of three posters at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, taking place f...
2024-10-17 18:39
962
Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M
MELBOURNE, Australia, Oct. 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended30 September 2024 (Q3 2024). Revenue update, full year guidance reaffirmed * Unaudited to...
2024-10-17 15:54
1572
KIND Announces Late-Breaking Abstract Accepted for Presentation on AND017 Clinical Trials to Treat Anemia in Chronic Kidney Disease (CKD) at ASN - Kidney Week 2024
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the late-br...
2024-10-17 15:44
1034
AXA Insurance Announces Strategic Name Change of "XL Re China" to "AXA International Re"
Reinforcing brand synergy and expanding reinsurance operations in mainland China HONG KONG, Oct. 17, 2024 /PRNewswire/ -- AXA China Region Insurance Company ( Bermuda) Limited ("AXA Insurance") is pleased to announce the official name change of XL Reinsurance (China) Company Limited ("XL Re China"...
2024-10-17 15:20
1409
Cambrex Opens New Stability Storage Facility in Durham, North Carolina
EAST RUTHERFORD, N.J., Oct. 17, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that their stability storage business, Q1 Scientific, has opened a new cGMP facility inDurham, North Carolina, expanding its capacity for envi...
2024-10-17 15:00
1343
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic...
2024-10-17 14:30
2976
Bio X Cell Announces Board of Director Appointments
A Leading Producer of Monoclonal Antibodies LEBANON, N.H., Oct. 17, 2024 /PRNewswire/ -- Bio X Cell, LLC ("BXC" or the "Company"), the world's leading producer of monoclonal antibodies for pre-clinicalin vivo research applications, is pleased to announce the appointments ofAlan Hirzel and Kevin ...
2024-10-17 14:00
1208
IND Application for a Phase Ⅲ Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved
SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK) jointly announced that an application for a phase III clinical study (Study ID: KN026-004) of the anti-HER2 bispecific antibody KN026 combine...
2024-10-17 10:15
1712
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabo...
2024-10-17 08:00
3413
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 312 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8700
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5793
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5179
